申舒斯醫療保健 SRTS 深 滬
已收盤 02-06 16:00:00 美东时间
5.04
+0.200
+4.13%
華盛通- 最 高5.15
- 今 開4.98
- 成交量 9.85万股
- 最 低 4.885
- 昨 收 4.84
- 總市值 8278.22万
- 52周最高 5.92
- 市盈率 靜 12.40
- 換手率 0.00%
- 52周最低 3.03
- 委 比 -76.58%
- 總股本 1642.50万
- 歷史最高 15.25
- 量 比 1.20
- 振 幅 5.48%
- 歷史最低 1.76
- 每 手 1
- 風險率 0.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sensus Healthcare Appoints Eric Sachetta as Director
Sensus Healthcare ( ($SRTS) ) has shared an announcement. On November 10, 2025,...
2025-11-13 23:27
电话会总结 ｜ Sensus SRTS Q3 2025 业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Sensus Healthcare (SRTS) Q3 2025业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **Q3 2025财务表现：** - 营收：690万美元，同比下降21.6%（Q3 2024为880万美元） - 毛利润：270万美元，同比下降48.1%（Q3 2024为520万美元） - 毛利率：39.1%，同比大幅下降20个百分点（Q3 2024为59.1%） - 净亏损：90万美元（每股亏损6美分），而Q3 2024为净利润120万美元（每股收益7美分） - 调整后EBITDA：负240万美元，而Q3 2024为正1
2025-11-07 12:07
Sensus Healthcare Faces Mixed Earnings Amid Challenges
Sensus Healthcare, Inc. (($SRTS)) has held its Q2 earnings call. Read on for th...
2025-08-13 09:18
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
2025-08-11 09:43
Sensus Healthcare Q2 EPS $(0.06) Misses $0.03 Estimate, Sales $7.315M Miss $9.301M Estimate
Sensus Healthcare (NASDAQ:SRTS) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.03 by 330.77 percent. This is a 160 percent decrease over earnings of $0.10 per share from
2025-08-08 04:18
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
2025-05-21 16:44
美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
2025-05-20 09:28
Maxim Group Maintains Buy on Sensus Healthcare, Lowers Price Target to $10
Maxim Group analyst Anthony Vendetti maintains Sensus Healthcare (NASDAQ:SRTS) with a Buy and lowers the price target from $14 to $10.
2025-05-19 23:56
Sensus Healthcare Q1 2025 GAAP EPS $(0.16) Down From $0.14 YoY, Sales $8.344M Beat $7.234M Estimate
Sensus Healthcare (NASDAQ:SRTS) reported quarterly losses of $(0.16) per share. This is a 214.29 percent decrease over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of
2025-05-16 04:17
美股大行评级 | 潜在涨幅1543.84%！Compass Therapeutics获HC Wainwright升目标价至24美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1115197988923084800.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Compass Therapeutics(CMPX)"买入"评级，目标价从10美元升至24美元</p> <p>• 瑞杰金融：维持Freeport-McMoRan(FCX)
2025-04-07 10:45
